Trial Profile
A Phase III study of HP-5070 in patients with primary palmar hyperhidrosis
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 09 Oct 2020
Price :
$35
*
At a glance
- Drugs Oxybutynin (Primary)
- Indications Hyperhidrosis
- Focus Registrational; Therapeutic Use
- Sponsors Hisamitsu Pharmaceutical
- 07 Oct 2020 According to a Hisamitsu Pharmaceutical media release, in the future, Hisamitsu pharmaceutical aims to apply for manufacturing and marketing approval during FY2022.
- 07 Oct 2020 Status changed from planning to recruiting, according to a Hisamitsu Pharmaceutical media release.
- 30 Oct 2018 New trial record